



News Release

December 4, 2025

PreveCeutical Announces Grant of Patent for Innovative Pain Therapy Technology

Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCID: PRVCF, FSE: 18H0) is pleased to announce that the Australian Patent Office has granted Australian Patent No. AU2020212659, titled “*A Cyclic Peptide*”, which relates to the Company’s pain therapy program. This patent represents a significant milestone in the development and protection of PreveCeutical’s proprietary technologies aimed at addressing unmet needs in pain management.

The granted patent provides protection in Australia for novel cyclized peptides that are analogues of dynorphin, an endogenous opioid peptide. These compounds are designed to deliver effective pain relief while potentially reducing the adverse effects commonly associated with traditional opioid therapies, such as dependence and tolerance. The invention also encompasses pharmaceutical compositions and methods of use for treating or preventing pain in subjects, reinforcing the therapeutic potential of this technology.

This patent is jointly owned by PreveCeutical Medical Inc. and The University of Queensland, reflecting the strength of the collaborative research partnership between the two organizations. The patent provides exclusivity in Australia until January 2040, subject to maintenance, and forms part of a broader patent family with corresponding applications pending in the United States, Europe, and Canada. This global strategy ensures robust protection for PreveCeutical’s intellectual property portfolio and supports its long-term commercialization objectives.

PreveCeutical’s pain therapy program focuses on developing next-generation peptide-based analgesics that aim to overcome the limitations of conventional opioids. By leveraging advanced peptide engineering and cyclization techniques, these candidates are designed to exhibit enhanced stability and receptor selectivity, which could significantly improve patient outcomes in managing acute and chronic pain.

PreveCeutical CEO Stephen Van Deventer commented: “*The grant of this patent is a significant achievement for PreveCeutical and underscores our commitment to pioneering innovative solutions for pain management. This intellectual property strengthens our position in a global market seeking safer alternatives to opioids and supports our long-term commercialization strategy.*”

Further details on the patent can be accessed through the Australian Patent Search at <https://ipsearch.ipaustralia.gov.au/patents/2020212659>.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on [Twitter](#) and [Facebook](#).

On behalf of the Board of Directors of PreveCeutical

Stephen Van Deventer, Chairman and Chief Executive Officer

For further information, please contact:

Stephen Van Deventer: +1 604 306 9669

Or Investor Relations ir@preveceutical.com

Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:

Certain information in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements in this news release include, but are not limited to the business focus of each of PreveCeutical and BioGene. Important factors that could cause actual results to differ materially from the parties' expectations include unanticipated market, economic and other conditions which may adversely affect the parties' ability to execute on their respective business plans, and other risks detailed from time to time in the filings made by the parties' with the securities regulatory authorities. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the PreveCeutical and BioGene. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the PreveCeutical and BioGene disclaim any intention or obligation to update or revise such information, except as required by applicable law.